Drug Trial Radar · NCT05574010
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
128
Actual
Start
Nov 15, 2022
Primary completion
Nov 29, 2024
Study completion May 19, 2025
Sponsor
- Lead sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SAIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Oct 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).
Conditions
- Celiac Disease
Interventions
Cohort 1 in Part ADrug
Dose 1 KAN-101 Intravenous (IV) infusion
Cohort 2 in Part ADrug
Dose 2 KAN-101 Intravenous (IV) infusion
Placebo: Group 1 in Part B and Part COther
Placebo Intravenous (IV) infusion
Group 2 in Part B and Part CDrug
Dose 3 KAN-101 Intravenous (IV) infusion
Group 3 in Part B and Part CDrug
Dose 4 KAN-101 Intravenous (IV) infusion
Group 4 in Part B and Part CDrug
Dose 5 KAN-101 Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of TEAEs as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) in Part ATime frame: From screening until the safety follow-up visit on Day 28
- Change in Pre- and Post-Gluten Challenge (GC) IL-2 Response From Baseline to Day 15Time frame: From Baseline screening to Day 15
- Change in IL-2 Response From Day 15 Pre-GC to Day 15 Post GCTime frame: 0 (pre-GC) and 4 hours post-GC on Day 15
Locations
36 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Anaheim Clinical Trials, LLC
Anaheim, California
GCP Research
St. Petersburg, Florida
Agile Clinical Research Trials
Sandy Springs, Georgia
Rush University Medical Center
Chicago, Illinois
Sneeze, Wheeze & Itch Associates, LLC
Normal, Illinois
Indiana University Health University Hospital
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
Mayo Clinic
Rochester, Minnesota
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota
Washington University School of Medicine
St Louis, Missouri
Quality Clinical Research
Omaha, Nebraska
Celiac Disease Center at Columbia University
New York, New York
North Carolina Clinical Research
Raleigh, North Carolina
Aventiv Research, Inc. d/b/a Centricity Research
Columbus, Ohio
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio
Northshore Gastroenterology Research, LLC
Westlake, Ohio
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas Health Science Center at Houston
Houston, Texas
Digestive Research of Central Texas
Waco, Texas
Advanced Research Institute
Ogden, Utah
Velocity Clinical Research, Salt Lake City
West Jordan, Utah
Campbelltown Hospital
Campbelltown, New South Wales, Australia
Wesley Research Institute
Auchenflower, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
St John of God Midland Public and Private Hospitals
Midland, Western Australia, Australia
Optimal Clinical Trials
Auckland, Auckland, New Zealand
PCRN Trials
Takapuna, Auckland, New Zealand
P3 Research - Tauranga
Tauranga, Bay of Plenty, New Zealand
Waikato Hospital
Hamilton, Hamilton, New Zealand
P3 Research - Dunedin
Dunedin, Otago, New Zealand
P3 Research - Palmerston North
Paraparaumu, Wellington Region, New Zealand
P3 Research - Wellington
Wellington, Wellington Region, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.